Hims and Hers Health Inc vs Payoneer Global Inc — how do they compare? Hims and Hers Health Inc trades at $28.43 (market cap $6.55B), while Payoneer Global Inc trades at $7.19 (market cap $2.43B). The key difference: Hims and Hers Health Inc is far larger — about 2.7× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Payoneer Global Inc for 61 Days on average.
| HIMS | PAYO | |
|---|---|---|
Market Cap | $6.55B | $2.43B |
Volume | 14,842,814 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $62.76 | $7.18 |
52-Week Low | $14.52 | $4.27 |
Typical Hold Time | 21 Days | 61 Days |
Enterprise Value | $7.25B | $2.17B |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Payoneer Global (PAYO) trades at $7.16, showing minimal daily movement with a 0.14% gain. The stock maintains a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, revenue grew to $821 million in 2025 with a 78% gross margin, but net income declined to $73 million. Recent news highlights the company's acquisition agreement with Nuvei and strategic expansion into India, while earnings show mixed quarterly performance with two misses and one beat in the last four quarters.
PAYO presents a mixed outlook with 60% analyst buy ratings supporting growth potential from international expansion and partnership renewals. However, declining profit margins, elevated P/E ratio of 51.18, and acquisition-related uncertainties pose significant risks. The stock's current technical strength contrasts with fundamental challenges, requiring careful monitoring of execution against growth initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →